Lanadelumab
- Generic Name
- Lanadelumab
- Brand Names
- Takhzyro
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1426055-14-2
- Unique Ingredient Identifier
- 2372V1TKXK
- Background
Lanadelumab, also known as DX-2930, is a human IgG1 monoclonal antibody designed for subcutaneous self-injection. It is a fully human immunoglobulin, k-light-chain made in recombinant Chinese Hamster Ovary cells. The FDA and EU granted the designation of priority review, breakthrough therapy and orphan drug for rare diseases based on the results of the repor...
- Indication
Lanadelumab is indicated for the prophylaxis treatment to prevent attacks in adult and pediatric patients aged 2 years and older with hereditary angioedema.
...
- Associated Conditions
- Acute attacks of hereditary angioedema, Recurrent Angioedema
- Associated Therapies
- -
A Study of Lanadelumab to Prevent Hereditary Angioedema (HAE) Attacks in Children
- First Posted Date
- 2019-08-28
- Last Posted Date
- 2022-05-26
- Lead Sponsor
- Shire
- Target Recruit Count
- 21
- Registration Number
- NCT04070326
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
🇩🇪Charité - Universitätsmedizin Berlin., Berlin, Germany
Study of Lanadelumab in Healthy Japanese and Matched Caucasian Adult Subjects
- First Posted Date
- 2018-01-17
- Last Posted Date
- 2021-06-03
- Lead Sponsor
- Shire
- Target Recruit Count
- 32
- Registration Number
- NCT03401671
- Locations
- 🇺🇸
WCCT Global, Inc., Cypress, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.